|
|
 Previous Article | Table of Contents | Next Article 
PU.1/Pip and Basic Helix Loop Helix Zipper Transcription Factors Interact With Binding Sites in the CD20 Promoter to Help Confer Lineage- and Stage-Specific Expression of CD20 in B Lymphocytes
Andreas Himmelmann,
Agostino Riva,
Gaye Lynn Wilson,
Brian P. Lucas,
Claire Thevenin, and
John H. Kehrl
From the B Cell Molecular Immunology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
CD20 is a B-lineage-specific gene expressed at the pre-B-cell stage of B-cell development that disappears on differentiation to plasma cells. As such, it serves as an excellent paradigm for the study of lineage and developmental stage-specific gene expression. Using in vivo footprinting we identified two sites in the promoter at -45 and -160 that were occupied only in CD20+ B cells. The -45 site is an E box that binds basic helix-loop-helix-zipper proteins whereas the -160 site is a composite PU.1 and Pip binding site. Transfection studies with reporter constructs and various expression vectors verified the importance of these sites. The composite PU.1 and Pip site likely accounts for both lineage and stage-specific expression of CD20 whereas the CD20 E box binding proteins enhance overall promoter activity and may link the promoter to a distant enhancer.
Blood, Vol. 90 No. 10 (November 15), 1997:
pp. 3984-3995
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Hiraga, A. Tomita, T. Sugimoto, K. Shimada, M. Ito, S. Nakamura, H. Kiyoi, T. Kinoshita, and T. Naoe
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Blood,
May 14, 2009;
113(20):
4885 - 4893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Shaffer, N.C. T. Emre, P. B. Romesser, and L. M. Staudt
IRF4: Immunity. Malignancy! Therapy?
Clin. Cancer Res.,
May 1, 2009;
15(9):
2954 - 2961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mankai, A. Bordron, Y. Renaudineau, C. Martins-Carvalho, S. Takahashi, I. Ghedira, C. Berthou, and P. Youinou
Purine-Rich Box-1-Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells
Cancer Res.,
September 15, 2008;
68(18):
7512 - 7519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Schweitzer, K. J. Huang, M. B. Kamath, A. V. Emelyanov, B. K. Birshtein, and R. P. DeKoter
Spi-C Has Opposing Effects to PU.1 on Gene Expression in Progenitor B Cells
J. Immunol.,
August 15, 2006;
177(4):
2195 - 2207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Liu and X. Ma
Interferon Regulatory Factor 8 Regulates RANTES Gene Transcription in Cooperation with Interferon Regulatory Factor-1, NF-{kappa}B, and PU.1
J. Biol. Chem.,
July 14, 2006;
281(28):
19188 - 19195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ushmorov, F. Leithauser, O. Sakk, A. Weinhausel, S. W. Popov, P. Moller, and T. Wirth
Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma
Blood,
March 15, 2006;
107(6):
2493 - 2500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. V. Pedchenko, G. Y. Park, M. Joo, T. S. Blackwell, and J. W. Christman
Inducible binding of PU.1 and interacting proteins to the Toll-like receptor 4 promoter during endotoxemia
Am J Physiol Lung Cell Mol Physiol,
September 1, 2005;
289(3):
L429 - L437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado
Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms
J. Immunol.,
June 15, 2005;
174(12):
7859 - 7868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny
From the bench to the bedside: ways to improve rituximab efficacy
Blood,
November 1, 2004;
104(9):
2635 - 2642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. van der Stoep, E. Quinten, M. M. Rezende, and P. J. van den Elsen
E47, IRF-4, and PU.1 synergize to induce B-cell-specific activation of the class II transactivator promoter III (CIITA-PIII)
Blood,
November 1, 2004;
104(9):
2849 - 2857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Schweitzer and R. P. DeKoter
Analysis of Gene Expression and Ig Transcription in PU.1/Spi-B-Deficient Progenitor B Cell Lines
J. Immunol.,
January 1, 2004;
172(1):
144 - 154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O'Reilly, C. M. Quinn, T. El-Shanawany, S. Gordon, and D. R. Greaves
Multiple Ets Factors and Interferon Regulatory Factor-4 Modulate CD68 Expression in a Cell Type-specific Manner
J. Biol. Chem.,
June 6, 2003;
278(24):
21909 - 21919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Du, M. J. Stankiewicz, Y. Liu, Q. Xi, J. E. Schmitz, J. A. Lekstrom-Himes, and S. J. Ackerman
Novel Combinatorial Interactions of GATA-1, PU.1, and C/EBPepsilon Isoforms Regulate Transcription of the Gene Encoding Eosinophil Granule Major Basic Protein
J. Biol. Chem.,
November 1, 2002;
277(45):
43481 - 43494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. D. Haro and R. Janknecht
Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter
Nucleic Acids Res.,
July 1, 2002;
30(13):
2972 - 2979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Torlakovic, A. Tierens, H. D. Dang, and J. Delabie
The Transcription Factor PU.1, Necessary for B-Cell Development Is Expressed in Lymphocyte Predominance, But Not Classical Hodgkin's Disease
Am. J. Pathol.,
November 1, 2001;
159(5):
1807 - 1814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Mitsiades, S. P. Treon, N. Mitsiades, Y. Shima, P. Richardson, R. Schlossman, T. Hideshima, and K. C. Anderson
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
Blood,
August 1, 2001;
98(3):
795 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Marecki, C. J. Riendeau, M. D. Liang, and M. J. Fenton
PU.1 and Multiple IFN Regulatory Factor Proteins Synergize to Mediate Transcriptional Activation of the Human IL-1{{beta}} Gene
J. Immunol.,
June 1, 2001;
166(11):
6829 - 6838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gupta, A. Anthony, and A. B. Pernis
Stage-Specific Modulation of IFN-Regulatory Factor 4 Function by Kruppel-Type Zinc Finger Proteins
J. Immunol.,
May 15, 2001;
166(10):
6104 - 6111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Grazia Cappiello, F. S. Sutterwala, G. Trinchieri, D. M. Mosser, and X. Ma
Suppression of IL-12 Transcription in Macrophages Following Fc{{gamma}} Receptor Ligation
J. Immunol.,
April 1, 2001;
166(7):
4498 - 4506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rehli, A. Poltorak, L. Schwarzfischer, S. W. Krause, R. Andreesen, and B. Beutler
PU.1 and Interferon Consensus Sequence-binding Protein Regulate the Myeloid Expression of the Human Toll-like Receptor 4 Gene
J. Biol. Chem.,
March 24, 2000;
275(13):
9773 - 9781.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gupta, M. Jiang, A. Anthony, and A. B. Pernis
Lineage-Specific Modulation of Interleukin 4 Signaling by Interferon Regulatory Factor 4
J. Exp. Med.,
December 20, 1999;
190(12):
1837 - 1848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rao, L. A. Garrett-Sinha, J. Yoon, and M. C. Simon
The Ets Factors PU.1 and Spi-B Regulate the Transcription in Vivo of P2Y10, a Lymphoid Restricted Heptahelical Receptor
J. Biol. Chem.,
November 26, 1999;
274(48):
34245 - 34252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-L. Li, W. Schlegel, A. J. Valente, and R. A. Clark
Critical Flanking Sequences of PU.1 Binding Sites in Myeloid-specific Promoters
J. Biol. Chem.,
November 5, 1999;
274(45):
32453 - 32460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Stutz and M. Woisetschlager
Functional Synergism of STAT6 with Either NF-{kappa}B or PU.1 to Mediate IL-4-Induced Activation of IgE Germline Gene Transcription
J. Immunol.,
October 15, 1999;
163(8):
4383 - 4391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rao, A. Matsumura, J. Yoon, and M. C. Simon
SPI-B Activates Transcription via a Unique Proline, Serine, and Threonine Domain and Exhibits DNA Binding Affinity Differences from PU.1
J. Biol. Chem.,
April 16, 1999;
274(16):
11115 - 11124.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Koshiba, D. L. Rosin, N. Hayashi, J. Linden, and M. V. Sitkovsky
Patterns of A2A Extracellular Adenosine Receptor Expression in Different Functional Subsets of Human Peripheral T Cells. Flow Cytometry Studies with Anti-A2A Receptor Monoclonal Antibodies
Mol. Pharmacol.,
March 1, 1999;
55(3):
614 - 624.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Rieske and J. M. R. Pongubala
AKT Induces Transcriptional Activity of PU.1 through Phosphorylation-mediated Modifications within Its Transactivation Domain
J. Biol. Chem.,
March 9, 2001;
276(11):
8460 - 8468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
